Previous research (the Gynecologic Oncology Group's GOG181B trial) has suggested that trastuzumab is inactive in HER2 / neu -
expressing endometrial carcinomas, and in the current study, nearly half of the participants «ultimately did not have tumoral HER2 / neu gene amplification,» Dr. Santin said.
Autocrine Prolactin Stimulates
Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy Endocrinology February 15, 2017 Keshuo Ding, Yan Yuan, Qing - Yun Chong, Yulu Yang, Rui Li, Xiaoni Li, Xiangjun Kong, Pengxu Qian, Zirui Xiong, Vijay Pandey, Lan Ma, Zhengsheng Wu, Peter E. Lobie, and Tao Zhu Advanced and recurrent endometrial carcinoma (EC) exhibits a poor response to chemotherapy and low survival rates.